Literature DB >> 9724785

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.

J L Heeney1, V J Teeuwsen, M van Gils, W M Bogers, C De Giuli Morghen, A Radaelli, S Barnett, B Morein, L Akerblom, Y Wang, T Lehner, D Davis.   

Abstract

One of the obstacles to AIDS vaccine development is the variability of HIV-1 within individuals and within infected populations, enabling viral escape from highly specific vaccine induced immune responses. An understanding of the different immune mechanisms capable of inhibiting HIV infection may be of benefit in the eventual design of vaccines effective against HIV-1 variants. To study this we first compared the immune responses induced in Rhesus monkeys by using two different immunization strategies based on the same vaccine strain of HIV-1. We then utilized a chimeric simian/HIV that expressed the envelope of a dual tropic HIV-1 escape variant isolated from a later time point from the same patient from which the vaccine strain was isolated. Upon challenge, one vaccine group was completely protected from infection, whereas all of the other vaccinees and controls became infected. Protected macaques developed highest titers of heterologous neutralizing antibodies, and consistently elevated HIV-1-specific T helper responses. Furthermore, only protected animals had markedly increased concentrations of RANTES, macrophage inflammatory proteins 1alpha and 1beta produced by circulating CD8(+) T cells. These results suggest that vaccine strategies that induce multiple effector mechanisms in concert with beta-chemokines may be desired in the generation of protective immune responses by HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724785      PMCID: PMC27976          DOI: 10.1073/pnas.95.18.10803

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

Review 2.  Protective immunity against HIV infection: has nature done the experiment for us?

Authors:  G M Shearer; M Clerici
Journal:  Immunol Today       Date:  1996-01

3.  Induction of TH1 and TH2 immunity in neonatal mice.

Authors:  T Forsthuber; H C Yip; P V Lehmann
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

4.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

Review 5.  Toward an understanding of the correlates of protective immunity to HIV infection.

Authors:  B F Haynes; G Pantaleo; A S Fauci
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

6.  Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.

Authors:  W A Paxton; S R Martin; D Tse; T R O'Brien; J Skurnick; N L VanDevanter; N Padian; J F Braun; D P Kotler; S M Wolinsky; R A Koup
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

7.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.

Authors:  S Rowland-Jones; J Sutton; K Ariyoshi; T Dong; F Gotch; S McAdam; D Whitby; S Sabally; A Gallimore; T Corrah
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

Authors:  P W Berman; K K Murthy; T Wrin; J C Vennari; E K Cobb; D J Eastman; M Champe; G R Nakamura; D Davison; M F Powell; J Bussiere; D P Francis; T Matthews; T J Gregory; J F Obijeski
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

9.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Authors:  M Girard; B Meignier; F Barré-Sinoussi; M P Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; L Rimsky; K Weinhold
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge.

Authors:  W M Bogers; H Niphuis; P ten Haaft; J D Laman; W Koornstra; J L Heeney
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

View more
  25 in total

1.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta.

Authors:  R Kamin-Lewis; S F Abdelwahab; C Trang; A Baker; A L DeVico; R C Gallo; G K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

3.  Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.

Authors:  R K S Ahmed; B Makitalo; K Karlen; C Nilsson; G Biberfeld; R Thorstensson
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

4.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 5.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

6.  Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Authors:  Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Authors:  O Scharf; H Golding; L R King; N Eller; D Frazier; B Golding; D E Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 9.  HIV infection and pathogenesis: what about chemokines?

Authors:  R C Gallo; A Garzino-Demo; A L DeVico
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

10.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.